To syndicate this article, or for more information, please contact us online or call (406) 862-5400.
BioLargo Inc. (OTCQB: BLGO), a developer of water, food, agriculture, healthcare, and energy technologies designed to solve the most widespread problems facing the world, recently announced that it was awarded the prestigious New Product Innovation Award for the Water Treatment Industry North America by Frost & Sullivan. Based on its recent analysis of industrial water and wastewater treatment, the company’s subsidiary was recognized as a leader.
Investors in the industrial water and wastewater management industry, including companies like Abtech Holdings Inc.’s (OTC: ABHD) treatment of fracking liquids or Seair’s (OTC: SARCF) broad focus on water treatment technologies, may want to take a closer look at the company given these recent developments. The company’s AOS Filter is capable of disinfecting at less than 1/20th the energy cost of its nearest competitor, greater than 100 times the efficiency, and more than 10 times faster – making it a natural choice across many industries.
Read the entire press release here:
BioLargo, Inc. (OTCQB: BLGO) — BioLargo’s subsidiary BioLargo Water, Inc. has been awarded the prestigious New Product Innovation Award for the Water Treatment Industry – North America by Frost & Sullivan. Frost & Sullivan has a global team of analysts and consultants continuously researching a wide range of markets and companies to identify those that consistently pursue or invest in new technologies, enabling them to serve their customers more effectively and grow at above-industry average. This involves extensive primary and secondary research across the entire value chain of specific products.
Based on its recent analysis of the industrial water and wastewater treatment technology market, Frost & Sullivan recognizes BioLargo Water, Inc. as the 2015 Technology Innovation leader in the North American water treatment market. BioLargo Water’s AOS Filter is a “low-cost, high-impact, sustainable clean water technology capturing the attention of leaders in academia, governments, and the industry worldwide,” states the Frost & Sullivan award. The AOS Filter utilizes BioLargo’s (www.BioLargo.com) patented and proprietary technology to achieve high rates of disinfection to treat industrial and tertiary wastewater in multiple industries.
The comprehensive report that accompanied the award states: “With applications ranging from food and agriculture to ballast water treatment, the AOS Filter demonstrates industry-leading decontamination and disinfection capabilities and is well-poised for further scale-up and successful commercialization in the tertiary and advanced wastewater treatment market.”
BioLargo CEO & President Dennis Calvert commented, “We are honored to have our technology recognized by a global research and consulting firm. Our AOS Filter can change wastewater management and usher in a new level of efficiency for industrial clients, and make clean water affordable around the globe.”
Each year, Frost & Sullivan presents Technology Innovation Awards to companies that have developed an innovative element in a product by leveraging leading-edge technologies. The awards recognize the value-added features/benefits of the products and technologies, and the increased ROI it offers customers, which increases customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.
About BioLargo, Inc.
BioLargo, Inc. (BLGO) makes life better by delivering technology-based products that help solve some of the most widespread problems threatening the world’s supply of water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter — a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry and is named the Technology Innovation Leader in the water treatment market by Frost & Sullivan. BioLargo also owns a 50% interest in the Isan System, which was honored with a “Top 50 Water Company for the 21st Century” award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2016.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2014.